Clinical Trials Logo

Cerebral Hemorrhage clinical trials

View clinical trials related to Cerebral Hemorrhage.

Filter by:

NCT ID: NCT00127283 Completed - Clinical trials for Acquired Bleeding Disorder

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

FAST
Start date: May 2005
Phase: Phase 3
Study type: Interventional

This trial is conducted in Asia, Europe, Middle East, North America, Oceania, and South America. The purpose of this study is to evaluate the treatment of Recombinant Factor VIIa (eptacog alfa (activated)) in patients with acute intracerebral bleeding. It is expected that more patients will recover without severe permanent disability after acute treatment with Recombinant Factor VIIa by reducing further intracerebral bleeding.

NCT ID: NCT00075959 Completed - Clinical trials for Intracerebral Hemorrhage

Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

Start date: August 2004
Phase: Phase 2
Study type: Interventional

This study will determine if NXY-059 is safe in patients with an acute stroke caused by bleeding in the central nervous system. The primary objective was to assess the safety and tolerability of NXY-059 compared to placebo.

NCT ID: NCT00033917 Completed - Prematurity Clinical Trials

Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial

Start date: September 1989
Phase: Phase 3
Study type: Interventional

The purpose of this multicenter trial is to determine if indomethacin prevents bleeding in the brain of very low birth weight preterm infants.

NCT ID: NCT00029315 Completed - Cerebral Hemorrhage Clinical Trials

Intraventricular Rt-PA in Patients With Intraventricular Hemorrhage

Start date: September 2001
Phase: Phase 2
Study type: Interventional

This is a study to evaluate how recombinant tissue plasminogen activator (rt-PA) is utilized in patients with intraventricular hemorrhage (IVH). rt-PA is a drug that has been shown to dissolve blood, and may allow intraventricular catheters to be more effective for a longer period of time.

NCT ID: NCT00014989 Completed - Cerebral Palsy Clinical Trials

Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)

BEAM
Start date: December 1997
Phase: Phase 3
Study type: Interventional

As many more premature infants survive, the numbers of these infants with health problems increases. The rate of cerebral palsy (CP) in extremely premature infants is approximately 20%. Magnesium sulfate, the most commonly used drug in the US to stop premature labor, may prevent CP. This trial tests whether magnesium sulfate given to a woman in labor with a premature fetus (24 to 31 weeks out of 40) will reduce the rate of death or moderate to severe CP in the children at 2 years. The children receive ultrasounds of their brains as infants and attend three follow-up visits over two years to assess their health and development.